Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Fundamentals
Mkt Cap
$9.05B
Volume
-
52W High
$382.54
52W Low
$202.99
PE Ratio
40.45
Avg. Volume
270,409.95
EPS (Annual)
$6.84
P/B
6.15
Rev/Employee
$1,319,084.75
Earnings
Nov 02
52
Neutral Sentiment
How do you feel about KRYS?
StocktwitsEarnings
$KRYS Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $2.05 down -22.93% YoY
• Reported revenue of $127.34M up 30.20% YoY
2
JFais
$KRYS - solid Q, $400M buyback + expanding rare disease pipeline.
Along with names like $ARGX and $MDGL, good (but painful) reminders that the best action is often inaction
1
Rayvio_News_Filter
$KRYS 🔄
Krystal Biotech, Inc.'s board authorized a share repurchase program of up to $400 million.
Prioritized by relevance
1
shoc24
$KRYS is ranked #8 in healthcare quality with a score of 89. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
BiotechSwings
Beat on both lines and $KRYS still gave back about 13% today
near $290 off a $332.29 close
VYJUVEK revenue $127.3 million, up 30% from a year ago
EPS $2.05 beat estimates, $1.2 billion in cash on hand
earnings beat, price pulled back. that combo is the part I am watching imo
shoc24
$KRYS reported before the open this morning. GAAP EPS of $2.05 beat the $1.79 analyst estimate by 14.5%, according to Stock Meadow. Revenue was USD 127M versus USD 126M expected.
KryptonResearch14
$KRYS Vyjuvek revenue rose 30 percent in Q3 to 127.3 million dollars, and the filing split shows basically all of that growth came from outside the United States. U.S. revenue was 95.3 million dollars in the quarter, up only about 2.6 percent, and 274.4 million dollars over nine months, down a touch from 277.1 million a year earlier, while Europe and Japan together added 88.5 million dollars over those nine months against 4.9 million a year earlier.
HotDiamondFingers
the weird one this morning: $KRYS beat and it is still red, ~4% lower premarket, 332.29 to ~320. adjusted EPS 2.05 vs 1.90 on the calendar, Vyjuvek revenue 127.3 million dollars, up 30%, plus a 400 million dollar buyback authorization. nothing in the headline numbers explains the dip, so it looks like the print was already in the price. premarket quote.
shoc24
$KRYS reports earnings tomorrow before the open. I'm bullish heading into the report: KRYS has beaten EPS estimates in 7 of its last 8 reports, according to Stock Meadow.
Link your Stocktwits account
Ask your agent for live sentiment, watchers, trending tickers, and news.